Six key changes to COPD-X guidelines

The Lung Foundation Australia has flagged changes to the COPD-X Guidelines following a new literature review, including:

  1. Long-acting muscarinic antagonist (LAMA) agents are similarly effective in preventing moderate-to-severe and severe COPD exacerbations.  However tiotropium dry powder inhaler is the only formulation which reduces severe exacerbations.
  2. Once-daily treatment with indacaterol via Breezhaler (150 μg) and tiotropium bromide via HandiHaler (18 μg) equally improve lung function in patients with severe